Newsylist real-time news trend intelligence
↓ Cooling Business 🔮 Newsylist predicts: fades by tomorrow medium confidence

European Regulator Calls for Amgen’s Tavneos to Have Authorization Revoked

European regulators are recommending the revocation of marketing authorization for Amgen's rare-disease drug Tavneos following new data.

6sources
6articles
4velocity
-74%since first seen
5h agofirst detected

Velocity timeline

How fast coverage is spreading — measured hourly from article rate × source diversity. How this works →

14950Jun 26 20:27Jun 27 01:30 UTC

The brief

The Committee for Medicinal Products for Human Use (CHMP) has reversed its endorsement of Tavneos, a drug used for an autoimmune disease. European regulators are now recommending that the marketing authorization for the Amgen-developed treatment be revoked.

Coverage from Reuters, the Wall Street Journal, Endpoints News, and Fierce Pharma emphasizes the shift in the regulator's position. Medscape reports that the decision to revoke the drug's status was driven by new data.

Attention now turns to an upcoming FDA hearing regarding the drug, as noted in coverage from Fierce Pharma.

Synthesized by Newsylist from the headlines below under a strict no-invention contract. ✓ fact-checked: all claims supported by sources Updated 5h ago.

Quick answers

What drug is facing authorization revocation?

The drug is Tavneos, developed by Amgen.

Why is the authorization being revoked?

According to Medscape, the decision was prompted by new data.

Which regulatory body issued the recommendation?

The recommendation was made by the CHMP (Committee for Medicinal Products for Human Use).

Coverage (6)

People, places & organizations

Topics

Related trends